Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2022-05-12 Earnings Release
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions "Item 2.02. Results of Operations and Financial Condition" and references a press release with preliminary unaudited revenue for a recent month. The document does not contain full financial statements or detailed financial analysis but rather announces preliminary financial results via a press release. The document length is 3378 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) correspond to an Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2022-05-12 English
FORM 3 SUBMISSION
Director's Dealing
2022-05-11 English
FORM 4 SUBMISSION
Director's Dealing
2022-05-11 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-04 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text includes an Item 2.02 section titled 'Results of Operations and Financial Condition' referencing a press release with first quarter financial results, and an Item 5.02 section announcing the appointment and promotion of a senior executive (Chief Operating Officer). The document does not contain full financial statements or detailed financial analysis itself but refers to a press release. The primary content is the management change announcement and a brief mention of earnings results. Given the detailed description of the executive appointment and compensation terms, the document fits best under Board/Management Information (MANG). The earnings press release is attached as an exhibit but is not the main document. Therefore, the classification is MANG with high confidence.
2022-05-04 English
FORM 4 SUBMISSION
Director's Dealing
2022-05-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.